Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Pathological Biomarkers in Precision Medicine
share announcement

Pathological Biomarkers in Precision Medicine

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 805

Special Issue Editors

Prof. Dr. Ovidiu Constantin Baltatu

E-Mail Website
Guest Editor
Center of Innovation, Technology and Education (CITE) at Anhembi Morumbi University—Anima Institute, Sao Jose dos Campos, Brazil
Interests: cardiovascular disease; innovative diagnostics; disease prevention strategies
Special Issues, Collections and Topics in MDPI journals
Dr. Mirela A. Dobre

E-Mail Website
Guest Editor
Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Interests: nephrology; kidney disease
Dr. Tudor Groza

E-Mail Website
Guest Editor
Rare Care Centre, Perth Children's Hospital, Nedlands, WA 6009, Australia
Interests: natural language processing; knowledge graphs; ontologies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the dynamic landscape of precision medicine, this Special Issue seeks to comprehensively explore pathological biomarkers via multifaceted methods. The identification and validation of pathological biomarkers have emerged as critical components in tailoring therapeutic interventions for individual patients. This Special Issue invites contributions spanning a broad spectrum of research areas, including but not limited to the following:

  • Biomarker Discovery and Validation: Research focusing on the identification, validation, and clinical translation of pathological biomarkers for various diseases, such as cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases.
  • Digital Biomarkers: Advancements in the identification and application of digital biomarkers, leveraging technologies for precise diagnostics and tailored therapeutic approaches.
  • Omics Data Integration: Innovations in integrating multi-omics data (genomics, transcriptomics, proteomics, metabolomics, and phenomics) and clinical data for a holistic understanding of disease mechanisms and personalized treatment strategies.
  • Digital Imaging Technologies: Advancements in medical imaging technologies, including radiomics, functional imaging, molecular imaging, computational pathology, and their role in refining diagnostics and biomarker detection.

We welcome original research articles and review papers that contribute to the deeper understanding of the importance of exploring more pathological biomarkers, with the ultimate goal of advancing precision medicine and improving patient outcomes.

Prof. Dr. Ovidiu Constantin Baltatu
Dr. Mirela A. Dobre
Dr. Tudor Groza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pathological biomarkers
  • precision medicine
  • artificial intelligence
  • medical imaging
  • omics data analysis
  • personalized medicine
  • biomarker discovery
  • digital pathology

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 1568 KiB  
Review
Evaluation of PAGE-B Score for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients: Reliability, Validity, and Responsiveness
by Evanthia Tourkochristou, Maria Kalafateli, Christos Triantos and Ioanna Aggeletopoulou
Biomedicines 2024, 12(6), 1260; https://doi.org/10.3390/biomedicines12061260 - 5 Jun 2024
Viewed by 416
Abstract
Chronic hepatitis B (CHB) constitutes a major global public health issue, affecting millions of individuals. Despite the implementation of robust vaccination programs, the hepatitis B virus (HBV) significantly influences morbidity and mortality rates. CHB emerges as one of the leading causes of hepatocellular [...] Read more.
Chronic hepatitis B (CHB) constitutes a major global public health issue, affecting millions of individuals. Despite the implementation of robust vaccination programs, the hepatitis B virus (HBV) significantly influences morbidity and mortality rates. CHB emerges as one of the leading causes of hepatocellular carcinoma (HCC), introducing a major challenge in the effective management of CHB patients. Therefore, it is of utmost clinical importance to diligently monitor individuals with CHB who are at high risk of HCC development. While various prognostic scores have been developed for surveillance and screening purposes, their accuracy in predicting HCC risk may be limited, particularly in patients under treatment with nucleos(t)ide analogues. The PAGE-B model, incorporating age, gender, and platelet count, has exhibited remarkable accuracy, validity, and reliability in predicting HCC occurrence among CHB patients receiving HBV treatment. Its predictive performance stands out, whether considered independently or in comparison to alternative HCC risk scoring systems. Furthermore, the introduction of targeted adjustments to the calculation of the PAGE-B score might have the potential to further improve its predictive accuracy. This review aims to evaluate the efficacy of the PAGE-B score as a dependable tool for accurate prediction of the development of HCC in CHB patients. The evidence discussed aims to provide valuable insights for guiding recommendations on HCC surveillance within this specific population. Full article
(This article belongs to the Special Issue Pathological Biomarkers in Precision Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop